VIKTORIA-2 Trial Evolves to Evaluate Gedatolisib in Endocrine-Sensitive and -Resistant Breast Cancer
Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...
CAR T therapy spreads beyond academic centers, but insurance, cost and policy gaps keep most eligible lymphoma patients from ...
FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response ...
A new program for young cancer patients breaks disease silos, showing how multidisciplinary teamwork improves coordination, ...
Dr. Doroshow addresses financial toxicity as a central concern in Sandra's case and broader challenge in HER2-directed ...
Complete response at 3 months was 79.6% (191/240), with duration-of-response estimates showing a gradual attrition over time ...
During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.
Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...
Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects ...
Andrzej Jakubowiak, MD, PhD, director of the multiple myeloma program at the University of Chicago, discusses the definitive results of the phase 3 ATLAS trial (NCT02659293), recently published in The ...
Dr. Leal introduces amifampridine, an FDA-approved oral potassium channel blocker that increases acetylcholine release at ...
Ultimately, Rathmell emphasizes that the BRIDGE Program represents a shift toward more holistic oncology care—one that aligns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results